Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Marizomib

EU orphan designation number: EU/3/14/1295   
Active ingredient: Marizomib
Indication: Treatment of plasma cell myeloma
Sponsor: Celgene Europe B.V.
Winthontlaan 6 N, 3526 KV Utrecht, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/08/2014 Orphan designation EMA/OD/035/14 (2014)5520 of 29/07/2014
13/02/2018 Transfer of orphan designation EMA/OD/035/14/T/01 (2018)941 of 9/02/2018
27/07/2018 Transfer of orphan designation EMA/OD/035/14/T/02 (2018)5063 of 25/07/2018